Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LT3001 Safety, PK, and Drug-Drug Interaction Study
NCT04809818Phase 1Completed
- Sponsor
- Lumosa Therapeutics
- Start
- Mar 2021
- Primary completion
- Aug 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of odatroltide in ischemic stroke, sponsored by Lumosa Therapeutics. Primary endpoint: Number of Adverse Events at 16 days. Started Mar 2021; status: completed.
02
Drugs
odatroltide
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT04809818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04809818.